M
Ming Lei
Researcher at Bristol-Myers Squibb
Publications - 7
Citations - 1599
Ming Lei is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Ipilimumab. The author has an hindex of 5, co-authored 7 publications receiving 183 citations.
Papers
More filters
Journal ArticleDOI
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y. Janjigian,Yelena Y. Janjigian,Kohei Shitara,Markus Moehler,Marcelo Garrido,Pamela Salman,Lin Shen,Lucjan Wyrwicz,Kensei Yamaguchi,Tomasz Skoczylas,Arinilda Silva Campos Bragagnoli,Tianshu Liu,Michael Schenker,Patricio Eduardo Yanez,Mustapha Tehfe,Ruben Dario Kowalyszyn,Michalis V. Karamouzis,Ricardo Bruges,Thomas Zander,Roberto Pazo-Cid,Erika Hitre,Kynan Feeney,James M. Cleary,Valerie Poulart,Dana Cullen,Ming Lei,H. Xiao,Kaoru Kondo,M. Li,Jaffer A. Ajani +29 more
TL;DR: The CheckMate 649 trial as discussed by the authors evaluated first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophage alogaryal adenocarcinoma.
Journal ArticleDOI
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J. Kelly,Jaffer A. Ajani,Jarosław Kużdżał,Thomas Zander,Eric Van Cutsem,Guillaume Piessen,Guillermo Mendez,Josephine Feliciano,Satoru Motoyama,Astrid Lièvre,Hope E. Uronis,Elena Elimova,Cecile Grootscholten,Karen Geboes,Syed Nabeel Zafar,Stephanie J Snow,Andrew H. Ko,Kynan Feeney,Michael Schenker,Piotr Kocoń,Jenny Zhang,Lili Zhu,Ming Lei,Prianka Singh,Kaoru Kondo,James M. Cleary,Markus Moehler +26 more
TL;DR: In this paper, no adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageaal...
Journal ArticleDOI
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
Ian Chau,Yuichiro Doki,Jaffer A. Ajani,Jianming Xu,Lucjan Wyrwicz,Satoru Motoyama,Takashi Ogata,Hisato Kawakami,Chih-Hung Hsu,Antoine Adenis,Farid El Hajbi,Maria Di Bartolomeo,Maria Ignez Braghiroli,Eva Holtved,Ioannis Xynos,Xuan Liu,Ming Lei,Kaoru Kondo,Ken Kato,Yuko Kitagawa +19 more
TL;DR: NIVO plus chemo and NIVO + IPI both demonstrated superior OS vs chemo, along with durable objective responses and acceptable safety, in pts with advanced ESCC, and each represents a potential new 1L treatment option.
Journal ArticleDOI
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
Michael J. Overman,Sara Lonardi,Ka Yeung Mark Wong,Heinz-Josef Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Raymond S. McDermott,Andrew G. Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Magali Svrcek,Ajlan Atasoy,Huanyu Zhao,Ming Lei,Scott Kopetz,Thierry André +18 more
TL;DR: Long-term follow-up with NIVO + low-dose IPI provides durable clinical benefit with deepening of response and a manageable safety profile with no new safety signals, demonstrating long-term benefit of NIVo + low the dose of IPI for previously treated pts with MSI-H/dMMR mCRC.
Journal ArticleDOI
A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW.
Sandzhar Abdullaev,Thierry André,Ming Lei,Heinz-Josef Lenz,James Novotny,Andrew Scott Paulson,Sabine Tejpar,Kentaro Yamazaki,Jean-Marie Ledeine +8 more
TL;DR: Patients with MSI-H/dMMR mCRC treated with CT have poorer outcomes than patients with microsatellite stable/MMR proficient mC RC treated with NIVO or IPI, suggests TSP266.